Form 4: Protagonist Therapeutics CMO Exercises Options and Sells Shares for Significant Gain

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, MD, executed a series of stock option exercises and subsequent common stock sales on June 9 and June 10, 2025, realizing substantial profits.

Summary

• On June 9, 2025, Arturo Molina, MD, Chief Medical Officer of Protagonist Therapeutics, Inc. (PTGX), exercised options to acquire 10,000 shares of common stock at an exercise price of $8.04 per share.
• Immediately following the exercise on June 9, 2025, Dr. Molina sold 10,000 shares of common stock at a weighted average price of $55.51 per share, generating a profit of approximately $474,700 from this transaction.
• On June 10, 2025, Dr. Molina again exercised options to acquire another 10,000 shares of common stock at the same exercise price of $8.04 per share.
• Subsequently on June 10, 2025, he sold these 10,000 shares of common stock at a weighted average price of $57.03 per share, resulting in an additional profit of approximately $489,900.
• The shares sold on June 9, 2025, ranged in price from $55.18 to $55.75, while those sold on June 10, 2025, ranged from $56.665 to $57.48.
• Following these transactions, Dr. Molina's direct beneficial ownership of common stock remained at 83,892 shares, while his beneficial ownership of stock options decreased to 75,971 options.
• The stock options exercised were part of a grant for a total of 127,500 shares, with vesting scheduled through November 7, 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While insider selling can sometimes be viewed negatively, these transactions appear to be routine exercises of vested options followed by sales for liquidity, indicating the executive is monetizing significant gains from the company's stock appreciation. This is a positive for the executive and reflects well on the stock's performance.

Positives

• The Chief Medical Officer realized significant profits totaling approximately $964,600 from exercising options at a low price ($8.04) and selling shares at substantially higher market prices ($55.51 and $57.03).
• The high sale prices indicate a strong appreciation in Protagonist Therapeutics' stock value since the options were granted, reflecting positively on the company's performance or market perception.

Negatives

• Insider selling, even if for routine liquidity or diversification, can sometimes be perceived by investors as a lack of conviction, although in this case, it appears to be a standard exercise-and-sell transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report (Form 4) and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's personal financial planning and monetization of vested equity.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a signal, though these transactions are common for executives monetizing vested equity and do not necessarily indicate a lack of confidence in the company's future.

Key Dates

Recommendation

Keywords

Protagonist Therapeutics, PTGX, Form 4, Insider Trading, Stock Options, Common Stock, Chief Medical Officer, Arturo Molina, SEC Filing, Beneficial Ownership